Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 5Breast Neoplasms 3Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Multiple Myeloma 1Multiple Endocrine Neoplasia 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1HER2-positive Metastatic Breast Cancer 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1

Interventions

Trastuzumab 2Radiotherapy 2Capecitabine 2tucatinib 1sapanisertib 1pertuzumab 1patritumab deruxtecan 1paclitaxel-Angiopep-2 conjugate 1omburtamab I-131 1fludarabine 1eribulin 1avelumab 1WP 744 1Temozolomide 1Spinal Puncture 1Rituximab 1Psychiatric Rehabilitation 1Phlebotomy 1Methotrexate 1Cyclophosphamide 1Amplified Fragment Length Polymorphism Analysis 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Neoplasms × pertuzumab × CNS × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡